MiMedx Group Reports Q1 2026 Earnings with Decline in Wound Care Sales and Restructuring Announcements
MiMedx Group reported Q1 2026 consolidated net sales of $59 million, a 33% year-over-year decline, driven by a 60% drop in wound care sales. The company announced a restructuring plan, including a 15% workforce reduction, and cut its 2026 revenue guidance to $260–$290 million. The decline in wound care sales was attributed to Medicare reimbursement changes and prior-authorization issues.
Topics: Medicare Reimbursement Q1 Earnings Restructuring Revenue Decline Surgical Sales Growth Wound Care Decline